EXHIBIT A

From: <u>Grossman, Dov</u>
To: <u>Kouyoumdjian, Philip Y.</u>

Cc: Genderson, Bruce; Perlman, Adam; Rydstrom, Jessica; Bowers, Seth; Picozzi, Ben; Ruzich, Richard T.; Scott, Ian; araucci@MNAT.com

Subject: RE: Stivarqa Schedule

Subject: RE: Stivarga Schedule

Date: Monday, March 25, 2019 9:43:19 AM

Phil,

I write in advance of our meet-and-confer call on Tuesday at 11:00 am ET. A dial in number is below. Again, please make sure that Apotex's local coursel is on the call

As reflected in my prior email correspondence, you had previously represented that Apotex had unexpired samples of its ANDA Product and that you would produce them in connection with this litigation. Bayer relied on that representation in agreeing to the schedule in this action—including Bayer's agreement to consolidate the suit concerning the '232 patent with the existing case involving the '553 and '107 patents—as well as the scope of discovery regarding the '232 patent. You subsequently informed me on March 12, 2019 that Apotex, in fact, did not have unexpired samples of its ANDA Product. I understand that you have taken a different position about what you represented, and I do not intend to debate that point here. I will note, however, that you informed us just last week that Apotex's samples expired in March 2018, which was months before the parties even began negotiating the revised schedule and long before you notified us in March 2019 that Apotex only had expired samples of its ANDA Product. Yet Apotex had known since our letter in August 2018 regarding the '232 patent that Bayer's intention was to obtain unexpired samples of the ANDA Product and test them.

Nevertheless, we have asked you whether Apotex would produce new samples of its ANDA Product so that we may test them. You have refused to do so. We asked (on the March 12 call) whether you would treat the expired samples as representative of the unexpired product, but you would not agree to that either. We asked when Apotex planned to prepare additional samples of its ANDA Product, but apparently that will not be done any time in the near future. We further inquired on what basis you believe you can challenge infringement while simultaneously refusing to provide us with unexpired samples of Apotex's ANDA Product, but you have not directly answered that question.

In light of the foregoing, there appear to be two options. The first is that, given the sequence of events here, Apotex should produce samples of its ANDA Product; if it refuses to do so, then Apotex should be barred from challenging infringement of the '232 patent. The second possibility, as an alternative, is that the litigation involving the '232 patent should be severed from the remainder of the case, and then stayed until which point in time Apotex produces new samples of its ANDA Product. Apotex would give Bayer advance notice of when it intends to produce such samples to allow Bayer time to prepare to test them, and then Apotex would immediately provide samples to Bayer once they are ready. The results of such testing would then set the course for what next steps would be necessary to resolve the dispute between Bayer and Apotex regarding the '232 patent.

Please be prepared to address these discovery/scheduling issues during the parties' call. Should Apotex fail to agree to produce unexpired samples of the ANDA Product during that call, we intend to promptly raise these issues with the Court.

Please use the following dial in number:

888-759-6037 2024345812

Regards,

Dov

 $\textbf{From:} \ \ \textbf{Kouyoumdjian, Philip Y. [mailto:pkouyoumdjian@taftlaw.com]}$

Sent: Friday, March 22, 2019 4:39 PM

To: Grossman, Dov < DGrossman@wc.com>

Cc: Genderson, Bruce <BGenderson@wc.com>; Perlman, Adam <APerlman@wc.com>; Rydstrom, Jessica <JRydstrom@wc.com>; Bowers, Seth <SBowers@wc.com>; Picozzi, Ben <BPicozzi@wc.com>; Ruzich, Richard T. <rruzich@taftlaw.com>; Scott, lan <iscott@taftlaw.com>; araucci@MNAT.com
Subject: RE: Stivarga Schedule

Dov, we will be available on Tuesday at $11\ \mathrm{am}.$

Taft /

Philip Y. Kouyoumdjian / Partner Taft Stettinius & Hollister LLP 14 Penn Plaza 225 West 34th Street Suite 2102 New York, NY 10122 Direct: 917.534.7180

 $\underline{www.taftlaw.com} \ / \ \underline{pkouyoumdjian@taftlaw.com}$

111 East Wacker Drive • Suite 2800, Chicago, IL 60601 Direct: 312.836.4026 • Fax: 312.966.8555

Subscribe to our law updates

From: Grossman, Dov < DGrossman@wc.com>



Cc: Genderson, Bruce <<u>BGenderson@wc.com</u>>; Perlman, Adam <<u>APerlman@wc.com</u>>; Rydstrom, Jessica <<u>JRydstrom@wc.com</u>>; Bowers, Seth

```
Regards.
Dov
Sent: Mar 22, 2019 11:53 AM
Subject: RE: Stivarga Schedule
Dov,
batches of its ANDA product.
this
Best,
Phil
```

Subject: RE: Stivarga Schedule

Phil - I am not available Monday but could do other times on Tuesday after 1030 am.

From: "Kouyoumdjian, Philip Y." pkouyoumdjian@taftlaw.com

Sent: Mar 22, 2019 3:56 PM

Sent: Friday, March 22, 2019 4:06 PM

To: "Grossman, Dov" < DGrossman@wc.com>

Cc: "Genderson, Bruce" < BGenderson@wc.com>; "Perlman, Adam" < APerlman@wc.com>; "Rydstrom, Jessica" < JRydstrom@wc.com>; "Bowers, Seth" <\subsection{Seth | Sewers@wc.com | Picozzi, Ben | Serious | Review | Sewers@wc.com | Picozzi, Ben | Severs@wc.com | Ruzich, Richard T. | Truzich@taftlaw.com | Sectt, Ian | Sectt@taftlaw.com | Sewers@wc.com | Picozzi, Ben | Pi "Raucci, Anthony D." araucci@MNAT.com>

Subject: RE: Stivarga Schedule

Are you available on Monday for the m&c?

Phil

Taft /

Philip Y. Kouyoumdjian / Partner Taft Stettinius & Hollister LLP 14 Penn Plaza 225 West 34th Street Suite 2102 New York, NY 10122

Direct: 917.534.7180

www.taftlaw.com
 / pkouyoumdjian@taftlaw.com
 mailto:pkouyoumdjian@taftlaw.com

111 East Wacker Drive • Suite 2800, Chicago, IL 60601

Direct: 312.836.4026 • Fax: 312.966.8555

Subscribe to our law updateshttp://taftlaw.com/news/subscribe>

From: Grossman, Dov < DGrossman@wc.com>

Sent: Friday, March 22, 2019 2:20 PM

Cc: Genderson, Bruce <<u>BGenderson@wc.com</u>>; Perlman, Adam <<u>APerlman@wc.com</u>>; Rydstrom, Jessica <<u>JRydstrom@wc.com</u>>; Bowers, Seth < SBowers@wc.com>; Picozzi, Ben < BPicozzi@wc.com>; Ruzich, Richard T. < rruzich@taftlaw.com>; Scott, Ian < iscott@taftlaw.com>; Raucci, Anthony D. <araucci@MNAT.com>

Subject: RE: Stivarga Schedule

Please let us know whether you are available for a meet and confer call with local counsel on Tuesday at 1:30 pm ET. We would like to discuss next steps given Apotex's positions and representations with respect to unexpired samples of its ANDA Product.

To: "Grossman, Dov" < DGrossman@wc.com < mailto: DGrossman@wc.com >>>

Cc: "Genderson, Bruce" <<u>BGenderson@wc.com</u><mailto:<u>BGenderson@wc.com</u>>>; "Perlman, Adam"

<<u>APerlman@wc.com</u><; "Rydstrom, Jessica" <<u>JRydstrom@wc.com</u><; "Bowers, Seth" <<u>SBowers@wc.com<mailto:SBowers@wc.com>>;</u> "Picozzi, Ben" <<u>BPicozzi@wc.com<mailto:BPicozzi@wc.com>>;</u> "Ruzich, Richard T." <<u>rruzich@taftlaw.com<mailto:rruzich@taftlaw.com</u>>>; "Scott, Ian" <<u>iscott@taftlaw.com<mailto:iscott@taftlaw.com</u>>>

We have already addressed your first question. Your request that Apotex make new, unexpired product is unreasonable and is completely outside the scope of Apotex's discovery obligations. As we have discussed, Apotex is in the process of providing you with samples of each of the three expired

Regarding your second inquiry, we understand that no new ANDA product is scheduled to be prepared. We have reached out to our client to confirm

From: Grossman, Dov <\textbf{DGrossman@wc.com}<mailto:DGrossman@wc.com}>> rodov Morob 21 2010 11.46 AM



Find authenticated court documents without watermarks at docketalarm.com.

 $To: Kouyoumdjian, Philip \ Y. < \underline{pkouyoumdjian@taftlaw.com} < \underline{mailto:pkouyoumdjian@taftlaw.com} >> \\$ Cc: Genderson, Bruce <BGenderson@wc.com<mailto:BGenderson@wc.com>>>; Perlman, Adam <APerlman@wc.com<mailto:APerlman@wc.com>>>; Rydstrom, Jessica <JRydstrom@wc.com<mailto:JRydstrom@wc.com>>; Bowers, Seth <SBowers@wc.com<mailto:SBowers@wc.com>>; Picozzi, Ben <BPicozzi@wc.com<mailto:BPicozzi@wc.com>>; Ruzich, Richard T. <rruzich@taftlaw.com<mailto:rruzich@taftlaw.com>>; Scott, Ian <iscott@taftlaw.com<mailto:iscott@taftlaw.com>> Subject: RE: Stivarga Schedule Phil, We have some follow-up questions in light of your email: 1) Am I correct that Apotex will not prepare new samples of its ANDA Product now so that we may test them? If so, what is the basis for Apotex's refusal?

2) If Apotex will not prepare new samples of its ANDA Product now, when does Apotex anticipate it will prepare new samples of its ANDA Product?

Please let us know the answers promptly, and no later than the end of this week, so that we can determine how to proceed given Apotex's prior representations.

Regards,

Dov

From: Kouyoumdjian, Philip Y. [mailto:pkouyoumdjian@taftlaw.com]

Sent: Wednesday, March 20, 2019 10:35 AM

 $To: Grossman, Dov < \underline{DGrossman@wc.com} < \underline{mailto:DGrossman@wc.com} < \underline$

Cc: Genderson, Bruce <BGenderson@wc.com<mailto:BGenderson@wc.com<mailto:BGenderson@wc.com%3cmailto:BGenderson@wc.com>>>>; Perlman, Adam <a href="mailto:APerlman@wc.com<mailto:APerlman@wc.com<mailto:APerlman@wc.com<mailto:APerlman@wc.com>>; Rydstrom, Jessica

<JRydstrom@wc.com<mailto:JRydstrom@wc.com<mailto:JRydstrom@wc.com</p>Seth

<SBowers@wc.com<mailto:SBowers@wc.com<mailto:SBowers@wc.com<smailto:SBowers@wc.com</p>

 $<\!\!BPicozzi@wc.com<\!mailto:BPicozzi@wc.com<\!mailto:BPicozzi@wc.com\\\!>>>; Ruzich, Richard T.$

<rruzich@taftlaw.com<mailto:rruzich@taftlaw.com<mailto:rruzich@taftlaw.com%3cmailto:rruzich@taftlaw.com>>>; Scott, Ian

<iscott@taftlaw.com<mailto:iscott@taftlaw.com<mailto:iscott@taftlaw.com%3cmailto:iscott@taftlaw.com>>>>

Subject: RE: Stivarga Schedule

Dov.

In our response to your March 14 email, we requested a meet and confer if you intended to seek to bar Apotex from contesting infringement. We do not agree that responding to the three questions in your email of March 15 is a necessary precursor to holding this meet and confer.

In the spirit of cooperation, however, we provide the following responses:

1) On what date did Apotex's samples of its ANDA Product expire?

RESPONSE: March 2018.

2) What criteria are being used to determine whether the samples of Apotex's ANDA Product are expired and who set/determined those criteria?

RESPONSE: See, e.g., https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm366082.pdf

3) On what basis do you believe you can contest infringement with respect to the '232 patent and yet fail to provide us with unexpired samples of Apotex's ANDA Product?

RESPONSE: This inquiry is an improper contention interrogatory to which we have already responded. See Apotex's responses to Plaintiffs' First Set of Interrogatories with respect to the '232 patent. Apotex reserves its right to supplement these and other responses.

We are available to meet and confer on these issues.

Best.

Phil

 $From: Grossman, Dov < \underline{DGrossman@wc.com} < \underline{mailto:DGrossman@wc.com} <$ Sent: Friday, March 15, 2019 8:28 AM To: Kouyoumdjian, Philip Y.



Cc: Genderson, Bruce <BGenderson@wc.com<mailto:BGenderson@wc.com<mailto:BGenderson@wc.com%3cmailto:BGenderson@wc.com>>>; Perlman, Adam <APerlman@wc.com<mailto:APerlman@wc.com<mailto:APerlman@wc.com<sex; Rydstrom, Jessica <JRydstrom@wc.com<mailto:JRydstrom@wc.com%3cmailto:JRydstrom@wc.com>>>; Rydstrom, Jessica <JRydstrom@wc.com<mailto:JRydstrom@wc.com%3cmailto:JRydstrom@wc.com>>>; Bowers, Seth <SBowers@wc.com<mailto:SBowers@wc.com<mailto:SBowers@wc.com%3cmailto:JRydstrom@wc.com>>>; Picozzi, Ben <BPicozzi@wc.com<mailto:BPicozzi@wc.com<mailto:BPicozzi@wc.com%3cmailto:BPicozzi@wc.com>>>; Ruzich, Richard T. <rruzich@taftlaw.com<mailto:rruzich@taftlaw.com<mailto:rruzich@taftlaw.com</m>>>; Scott, Ian <iscott@taftlaw.com<mailto:iscott@taftlaw.com<mailto:iscott@taftlaw.com<mailto:iscott@taftlaw.com>>> Subject: RE: Stivarga Schedule

Phil.

I am not going to provide a point by point response to your email, but to be clear we disagree with your characterization of events. Nevertheless, if Apotex would like to meet and confer further about these issues, we can do so. However, in order to make such a call as productive as possible, please provide us with the following information in advance:

- 1) On what date did Apotex's samples of its ANDA Product expire?
- 2) What criteria are being used to determine whether the samples of Apotex's ANDA Product are expired and who set/determined those criteria?
- 3) On what basis do you believe you can contest infringement with respect to the '232 patent and yet fail to provide us with unexpired samples of Apotex's ANDA Product?

Please let us know when we can receive this information.

Regards.

Dov

 $From: Kouyoumdjian, Philip\ Y.\ [\underline{mailto:pkouyoumdjian@taftlaw.com}]$

Sent: Thursday, March 14, 2019 4:10 PM

To: Grossman@wc.com < nailto: DGrossman@wc.com < mailto: DGrossman@wc.com

 $Cc: Genderson, Bruce < \underline{BGenderson@wc.com} < \underline{mailto:BGenderson@wc.com} < \underline{mailto:BGenderso$

 $Perlman, Adam < \underline{APerlman@wc.com} < \underline{mailto:} \underline{APerlman@wc.com} < \underline{mailto:} \underline{APerlman@wc.com} > > ; Rydstrom, Jessica + \underline{mailto:} \underline{APerlman@wc.com} < \underline{mailto:} \underline{APerlman@wc.com} > > ; Rydstrom, Jessica + \underline{mailto:} \underline{APerlman@wc.com} < \underline{mailto:} \underline{APerlman@wc.com} > > ; Rydstrom, Jessica + \underline{mailt$

 $<\!\!I\!Rydstrom@wc.com<\!mailto:\!J\!Rydstrom@wc.com<\!scanilto:\!J\!Rydstrom@wc.com>\!>>; Bowers, Seth$

<<u>SBowers@wc.com<mailto:SBowers@wc.com<mailto:SBowers@wc.com%3cmailto:SBowers@wc.com>>>>; Picozzi, Ben</u>

<BPicozzi@wc.com<mailto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozzi@wc.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com<msilto:BPicozy.com

Subject: RE: Stivarga Schedule

Dov

We are disappointed that you intend to seek to bar Apotex from contesting infringement in this action if Apotex does not provide you with unexpired ANDA product. Any motion to strike our noninfringement defenses with respect to the '232 patent would be both meritless and frivolous under the Federal and Local Rules.

Your assertions that we represented to you that Apotex would (or could) produce unexpired samples of its ANDA product are both factually incorrect and wholly unsupported. As the correspondence attached to your email of today clearly shows, we never suggested, either explicitly or implicitly, that Apotex had unexpired ANDA product. We have consistently maintained that we would provide you with sample ANDA product "[t]o the extent possible," and have diligently worked toward that end. See email of P. Kouyoumdjian to D. Grossman, Oct. 31, 2018. None of our emails to you contains even a modicum of evidence that we had any knowledge that Apotex's ANDA product was expired. Upon learning that Apotex's sample tablets were expired, we informed you immediately. As we stated during our discussion on March 12, we are, nonetheless, prepared to provide you with samples of Apotex's expired ANDA products that you can make available to your experts for testing, if you so choose.

We explicitly notified you that Apotex's API samples were expired, at least as early as November 19, 2018. See email of D. Grossman to P. Kouyoumdjian, Nov. 19, 2018. We have been making every effort to provide you with unexpired API samples. To that end, we informed you that the supplier could only forward the samples to one of your experts. However, you have yet to provide us with the complete contact information that we requested to fulfill the shipment. Please provide the necessary requested information as soon as possible so that we can have the shipment effected as requested in our correspondence of today. See attached letter.

As an important aside, your email of today fails to indicate how Bayer is prejudiced by its current awareness that Apotex has no unexpired ANDA product. If you believe the present case schedule and the scope of discovery need to be amended because Apotex does not possess unexpired ANDA product, we are willing to meet and confer to discuss these issues. However, your request that Apotex somehow make or obtain new, unexpired product is patently unreasonable and completely outside the scope of Apotex's discovery obligations.

As to the schedule, the expert discovery deadline for Bayer to serve its infringement report on Apotex is May 15, 2019. If you intend to move forward with your threat to seek relief from the Court to bar Apotex from contesting infringement in this action, we request an immediate meet-and-confer. We, of course, are prepared to seek any and all redress for being forced to respond to any such filing with this Court.

Best, Phil

From: Grossman, Dov <<u>DGrossman@wc.com</u><mailto:<u>DGrossman@wc.com</u><mailto:<u>DGrossman@wc.com</u></m>
Sent: Thursday, March 14, 2019 9:12 AM
To: Kouyoumdjian, Philip Y.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

